Xtl Biopharmaceuticals Ltd Stock Fundamentals
| XTLB Stock | USD 2.10 0.22 11.70% |
XTL Biopharmaceuticals Ltd fundamentals help investors to digest information that contributes to XTL Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of XTL Stock. The fundamental analysis module provides a way to measure XTL Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTL Biopharmaceutica stock.
At present, XTL Biopharmaceutica's Interest Expense is projected to increase significantly based on the last few years of reporting. Total Revenue is expected to grow at the current pace this year, whereas Other Operating Expenses is forecasted to decline to about 726.8 K. XTL | Select Account or Indicator |
XTL Biopharmaceuticals Ltd Company Shares Owned By Institutions Analysis
XTL Biopharmaceutica's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current XTL Biopharmaceutica Shares Owned By Institutions | 1.92 % |
Most of XTL Biopharmaceutica's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XTL Biopharmaceuticals Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 1.918999999999999% of XTL Biopharmaceuticals Ltd are shares owned by institutions. This is 95.7% lower than that of the Biotechnology sector and 95.96% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 95.11% higher than that of the company.
XTL Biopharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XTL Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare XTL Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XTL Biopharmaceutica competition to find correlations between indicators driving XTL Biopharmaceutica's intrinsic value. More Info.XTL Biopharmaceuticals Ltd is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . At present, XTL Biopharmaceutica's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XTL Biopharmaceutica's earnings, one of the primary drivers of an investment's value.XTL Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XTL Biopharmaceutica's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XTL Biopharmaceutica could also be used in its relative valuation, which is a method of valuing XTL Biopharmaceutica by comparing valuation metrics of similar companies.XTL Biopharmaceutica is currently under evaluation in shares owned by institutions category among its peers.
XTL Biopharmaceutica Current Valuation Drivers
We derive many important indicators used in calculating different scores of XTL Biopharmaceutica from analyzing XTL Biopharmaceutica's financial statements. These drivers represent accounts that assess XTL Biopharmaceutica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XTL Biopharmaceutica's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 69.9K | 156.7K | 170.4K | 66.6K | 5.1M | 5.4M | |
| Enterprise Value | (4.4M) | (3.5M) | (2.8M) | (2.0M) | 3.7M | 3.9M |
XTL Biopharmaceutica ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, XTL Biopharmaceutica's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to XTL Biopharmaceutica's managers, analysts, and investors.Environmental | Governance | Social |
XTL Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 6.43 M | ||||
| Shares Outstanding | 5.45 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 1.92 % | ||||
| Number Of Shares Shorted | 70.82 K | ||||
| Price To Earning | 4.50 X | ||||
| Price To Book | 3.79 X | ||||
| EBITDA | (764 K) | ||||
| Net Income | (1.78 M) | ||||
| Cash And Equivalents | 5.16 M | ||||
| Cash Per Share | 0.95 X | ||||
| Total Debt | 206 K | ||||
| Current Ratio | 31.26 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (707 K) | ||||
| Short Ratio | 3.35 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 30.0 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 10.24 M | ||||
| Total Asset | 2.43 M | ||||
| Retained Earnings | (158.25 M) | ||||
| Working Capital | 1.84 M | ||||
| Current Asset | 3 M | ||||
| Net Asset | 2.43 M |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 31.5 K | 29.9 K | |
| Cost Of Revenue | 900.00 | 855.00 | |
| Stock Based Compensation To Revenue | (0.03) | (0.03) | |
| Sales General And Administrative To Revenue | 0.96 | 1.68 | |
| Research And Ddevelopement To Revenue | 0.05 | 0.05 | |
| Capex To Revenue | 0.03 | 0.04 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (1.10) | (1.15) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out XTL Biopharmaceutica Piotroski F Score and XTL Biopharmaceutica Altman Z Score analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.